Revvity Inc. (RVTY) shares plummeted 5.58% during intraday trading on Monday, marking a significant reversal from earlier gains.

The decline came despite the company reporting better-than-expected fourth-quarter adjusted earnings and revenue, along with issuing full-year 2026 guidance that exceeded analyst estimates. However, executives noted during their conference call that the company continues to face drug-related volume pressures in China and expects both first and second quarter 2026 operating margins to be lighter than normal. Additionally, the company anticipates its China index to be down slightly in the second half of 2026, contributing to investor concerns about near-term challenges.